OGN vs UPB · P/E 3.4, rev $6.40B vs rev $2.4M
Organon & Co (OGN) versus Upstream Bio, Inc. (UPB) — a side-by-side from cached financials, not a winner call.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Upstream Bio, Inc. (UPB) is a biotechnology company listed on US.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Latest reported UPB revenue for 2024-12-31 was $2.4M. Net income was -$62.8M. Revenue was down 0.4% from 2023-12-31 to 2024-12-31. UPB currently screens at market cap $407.3M.
OGN currently screens at market cap $2.52B and trailing P/E 3.4. UPB currently screens at market cap $407.3M.
Not investment advice. Open the OGN and UPB stock pages for the full models.
Not investment advice.